Immunome (IMNM)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from IMNM's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Immunome's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $14M | $9M | $7M |
| Net income | -$25M | -$37M | -$107M | -$293M | -$212M |
| Free cash flow | -$18M | -$29M | -$8M | -$118M | -$201M |
| EPS (diluted) | -$2.14 | -$3.09 | -$5.38 | -$5.00 | -$2.43 |
| Operating margin | — | — | -781.4% | -3382.4% | -3228.8% |
Superinvestors who own IMNM
From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| PRIMECAP Management PRIMECAP Management Co |
Trimmed | $97M | 0.06% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Trimmed | $249,618 | 0.0% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Held | $214,019 | 0.0% | Q2 2026 |
Insider buying
Open-market purchases by Immunome's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you. Every purchase since records began.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Mar 11, 2026 | Jean Jacques Bienaime |
1,000 | $21.55 | $21,550 |
| Dec 30, 2025 | Clay B Siegall |
4,729 | $21.15 | $100,018 |
| Dec 19, 2025 | Clay B Siegall |
7,278 | $20.48 | $149,053 |
| Dec 19, 2025 | Philip Tsai |
10,000 | $20.49 | $204,900 |
| Dec 18, 2025 | Clay B Siegall |
46,511 | $21.50 | $999,986 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when IMNM trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Immunome insiders buying the stock?
5 open-market insider purchases of IMNM in the last 12 months, from SEC Form 4 filings.
Which superinvestors own Immunome?
3 of the superinvestors Investingly tracks hold IMNM in their latest 13F, including PRIMECAP Management, Cliff Asness, Joel Greenblatt.
Companies like Immunome
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.